title: [Advances in measles virus for cancer therapy].
abstract: Oncolytic virotherapy is a novel cancer therapy. Vaccine-attenuated strains of measles virus(MV)is an ideal candidate for oncolytic virotherapy which has an excellent safety record. Vaccine-attenuated MV uses CD46 and Nectin-4 molecule as major entry receptors into cells. Vaccine-attenuated MV can selectively infect and kill a wide variety of cancer cells in vitro and in vivo. With the development of molecular cloning, scientists have successfully rescued cDNA of vaccine-attenuated MV and increased its oncolytic efficiency with molecular engineering techniques. Phase I clinical trials of virotherapy for ovarian cancer and multiple myeloma with vaccine-attenuated MV are underway. The preliminary results indicate the promising antitumor potential of vaccine-attenuated MV.
authors.affiliation: Pediatric Health Care Department, the Children's Hospital Zhejiang University School of Medicine, Hangzhou 310003, China.
authors.forename: Duo
authors.initials: D
authors.lastname: Zhou
authors.affiliation: Pediatric Health Care Department, the Children's Hospital Zhejiang University School of Medicine, Hangzhou 310003, China.
authors.forename: Zheng-yan
authors.initials: ZY
authors.lastname: Zhao
mesh_terms: D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D008459:Measles virus; D009369:Neoplasms / Q000628:therapy*; D050130:Oncolytic Virotherapy